Home/Filings/4/0001562180-25-000229
4//SEC Filing

Elston George 4

Accession 0001562180-25-000229

CIK 0001314102other

Filed

Jan 6, 7:00 PM ET

Accepted

Jan 7, 4:04 PM ET

Size

19.1 KB

Accession

0001562180-25-000229

Insider Transaction Report

Form 4
Period: 2025-01-03
Elston George
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2025-01-05+15,00063,356 total
  • Exercise/Conversion

    Common Stock

    2025-01-06+15,28573,374 total
  • Award

    Restricted Stock Units

    2025-01-03+59,00074,000 total
    Exercise: $0.00Common Stock (59,000 underlying)
  • Award

    Stock Option (Right to Buy)

    2025-01-03+117,000117,000 total
    Exercise: $8.26Exp: 2035-01-03Common Stock (117,000 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2025-01-0515,00030,000 total
    Exercise: $0.00Common Stock (15,000 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2025-01-0615,28514,715 total
    Exercise: $0.00Common Stock (15,285 underlying)
  • Tax Payment

    Common Stock

    2025-01-05$8.26/sh5,267$43,50558,089 total
  • Tax Payment

    Common Stock

    2025-01-06$8.68/sh4,808$41,73368,566 total
Footnotes (6)
  • [F1]Includes 876 shares acquired on July 31, 2024 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.
  • [F2]No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units.
  • [F3]The restricted stock units will vest in three ratable annual installments beginning January 3, 2026.
  • [F4]The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years.
  • [F5]The restricted stock units vests in three ratable annual installments beginning January 5, 2025.
  • [F6]The restricted stock units vests in three ratable annual installments beginning January 6, 2024.

Issuer

EyePoint Pharmaceuticals, Inc.

CIK 0001314102

Entity typeother

Related Parties

1
  • filerCIK 0001429932

Filing Metadata

Form type
4
Filed
Jan 6, 7:00 PM ET
Accepted
Jan 7, 4:04 PM ET
Size
19.1 KB